Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.39 |
| ▸ | P4HB | P07237 | 1/20 | 0.38 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.37 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.37 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.35 |
| ▸ | HTR3B | O95264 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.35 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27033249 | 0.78 | AOC3 (0.53) | AOC3CYP3A4MAPTP4HBTXNRD1 | |
| SCHEMBL12865263 | 0.75 | AOC3 (0.50) | AOC3CYP3A4MAPTKMT2AMEN1 | |
| SCHEMBL12613198 | 0.75 | AOC3 (0.42) | AOC3CYP3A4P4HBTXNRD1TXNRD3 | |
| SCHEMBL1768456 | 0.75 | AOC3 (0.50) | AOC3CYP3A4TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL30507560 | 0.75 | AOC3 (0.50) | AOC3CYP3A4MAPTKMT2AMEN1 | |
| SCHEMBL4031896 | 0.75 | AOC3 (0.50) | AOC3CYP3A4MAPTKMT2AMEN1 | |
| SCHEMBL12119917 | 0.75 | NQO2 (0.44) | AOC3CYP3A4KMT2AMEN1P4HB | |
| SCHEMBL3672985 | 0.75 | AOC3 (0.50) | AOC3CYP3A4MAPTKMT2ATXNRD1 | |
| SCHEMBL27967472 | 0.75 | AOC3 (0.50) | AOC3CYP3A4MAPTKMT2AMEN1 | |
| SCHEMBL8468090 | 0.74 | AOC3 (0.49) | AOC3CYP3A4MAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501516-B2 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2009-03-10 | — | — | US | disclosed |
| EP-1381599-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-09-24 | — | — | EP | disclosed |
| US-7223756-B2 | Quinazoline compounds with therapeutic use | ASTRAZENECA AB (SE) | 2007-05-29 | — | — | US | disclosed |
| US-7141577-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2006-11-28 | — | — | US | disclosed |
| EP-1409481-B1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-10-04 | — | — | EP | disclosed |
| US-20050009850-A1 | Quinazoline compounds with therapeutic use | ASTRAZENECA AB (SE) | 2005-01-13 | — | — | US | disclosed |
| US-20050009867-A1 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2005-01-13 | — | — | US | disclosed |
| EP-1451180-A1 | QUINAZOLINE COMPOUNDS WITH THERAPEUTIC USE | Astrazeneca AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| US-20040138240-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | US | disclosed |
| EP-1409481-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | Astrazeneca AB (SE) | 2004-04-21 | — | — | EP | disclosed |
| EP-1381599-A1 | QUINAZOLINE DERIVATIVES | Astrazeneca AB (SE) | 2004-01-21 | — | — | EP | disclosed |
| WO-2003047582-A1 | QUINOLINE DERIVATIVES AS ANTITUMOUR AGENTS | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003045943-A1 | QUINAZOLINE COMPOUNDS WITH THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | disclosed |
| WO-2003008409-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-01-30 | — | — | WO | disclosed |
| WO-2002085895-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138240-A1 | Quinazoline derivatives | NQO2, WEE1, CMA1 | AOC3 2172/4885CYP3A4 498/4885MAPT 4463/4885 |
| US-20050009850-A1 | Quinazoline compounds with therapeutic use | CD4, HLA-DRB1, IL5 | AOC3 2562/4885CYP3A4 1123/4885MAPT 3172/4885 |
| US-20050009867-A1 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ABL1, FLT3, JAK2 | AOC3 3648/4885CYP3A4 1743/4885MAPT 2233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.